These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
35. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Jaffe GJ; Ben-Nun J; Guo H; Dunn JP; Ashton P Ophthalmology; 2000 Nov; 107(11):2024-33. PubMed ID: 11054326 [TBL] [Abstract][Full Text] [Related]
36. Locally administered ocular corticosteroids: benefits and risks. McGhee CN; Dean S; Danesh-Meyer H Drug Saf; 2002; 25(1):33-55. PubMed ID: 11820911 [TBL] [Abstract][Full Text] [Related]
37. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Nguyen QD; Merrill PT; Jaffe GJ; Dick AD; Kurup SK; Sheppard J; Schlaen A; Pavesio C; Cimino L; Van Calster J; Camez AA; Kwatra NV; Song AP; Kron M; Tari S; Brézin AP Lancet; 2016 Sep; 388(10050):1183-92. PubMed ID: 27542302 [TBL] [Abstract][Full Text] [Related]
38. Retisert: is the new advance in treatment of uveitis a good one? Mohammad DA; Sweet BV; Elner SG Ann Pharmacother; 2007 Mar; 41(3):449-54. PubMed ID: 17341531 [TBL] [Abstract][Full Text] [Related]
39. [Corticosteroids in ophthalmology]. Trzcińska-Dabrowska Z Pol Tyg Lek; 1972 Jun; 27(26):1008-10. PubMed ID: 4560602 [No Abstract] [Full Text] [Related]
40. Controlled release of corticosteroid with biodegradable nanoparticles for treating experimental autoimmune uveitis. Luo L; Yang J; Oh Y; Hartsock MJ; Xia S; Kim YC; Ding Z; Meng T; Eberhart CG; Ensign LM; Thorne JE; Stark WJ; Duh EJ; Xu Q; Hanes J J Control Release; 2019 Feb; 296():68-80. PubMed ID: 30660629 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]